40 results on '"Hanna, Nawar"'
Search Results
2. MP49-09 ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LYMPH NODE POSITIVE SQUAMOUS CELL CARCINOMA OF THE PENIS: ANALYSIS OF THE NATIONAL CANCER DATA BASE
3. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis
4. MP71-09 EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY AFTER RADICAL NEPHROURETERECTOMY FOR LOCALLY ADVANCED AND/OR POSITIVE REGIONAL LYMPH NODE UPPER TRACT UROTHELIAL CARCINOMA
5. MP38-19 MULTIPARAMETRIC MRI/ULTRASOUND FUSION BIOPSY IMPROVES BUT DOES NOT REPLACE STANDARD TEMPLATE BIOPSY FOR THE DETECTION OF PROSTATE CANCER
6. MP22-04 RACIAL DISPARITIES IN THE TREATMENT AND SURVIVAL OF METASTATIC RENAL CELL CARCINOMA
7. PD67-09 COMPARATIVE EFFECTIVNESS OF ROBOT-ASSISTED VS. OPEN RADICAL CYSTECTOMY
8. MP28-08 REFUSAL OF PROSTATE-SPECIFIC ANTIGEN TESTING IN THE UNITED STATES
9. PD04-06 CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA: AN ANALYSIS OF THE NATIONAL CANCER DATA BASE
10. MP01-18 THE POTENTIAL IMPACT OF NEOADJUVANT CHEMOTHERAPY ON PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR NON-UROTHELIAL MUSCLE INVASIVE BLADDER CANCER
11. MP03-15 TRENDS IN TREATMENT STRATEGIES FOR METASTATIC RENAL CELL CARCINOMA
12. MP65-20 SLING PROCEDURES FOR FEMALE STRESS INCONTINENCE: DOES SURGICAL SPECIALTY MATTER?
13. MP01-04 ONCOLOGIC AND PERIOPERATIVE OUTCOMES OF “CYTOREDUCTIVE” RADICAL CYSTECTOMY FOR PATIENTS WITH METASTATIC BLADDER CANCER IN THE UNITED STATES
14. MP63-06 RACIAL DISPARITIES IN QUALITY METRICS OF MUSCLE INVASIVE BLADDER CANCER
15. MP21-10 THE IMPACT OF MEDICARE ELIGIBILITY ON PROSTATE CANCER SCREENING BEHAVIORS
16. PI-04 SURGEON AND HOSPITAL VARIATION IN THE COSTS OF ROBOT-ASSISTED RADICAL PROSTATECTOMY IN THE UNITED STATES
17. MP37-02 INFORMED DECISION-MAKING FOR PROSTATE-SPECIFIC ANTIGEN SCREENING
18. MP78-07 THE IMPORTANCE OF OTHER CAUSE MORTALITY AND CARDIOVASCULAR MORBIDITY IN PATIENTS WITH METASTATIC PROSTATE CANCER EXPOSED TO CONVENTIONAL ANDROGEN DEPRIVATION THERAPY
19. MP60-11 90-DAY MORTALITY REPRESENTS A MORE REALISTIC ENDPOINT THAN 30-DAY MORTALITY AFTER RADICAL CYSTECTOMY
20. MP37-07 COMPARATIVE EFFECTIVENESS OF ROBOTIC-ASSISTED VERSUS OPEN RADICAL PROSTATECTOMY CANCER CONTROL OUTCOMES
21. MP60-17 SUBOPTIMAL USE OF NEOADJUVANT OR ADJUVANT CHEMOTHERAPY IN RADICAL CYSTECTOMY PATIENTS: A POPULATION-BASED STUDY
22. MP10-19 DEVELOPMENT AND EXTERNAL VALIDATION OF A PROGNOSTIC TOOL FOR PREDICTION OF CANCER-SPECIFIC MORTALITY AFTER COMPLETE LOCO-REGIONAL PATHOLOGICAL STAGING FOR SQUAMOUS CELL CARCINOMA OF THE PENIS
23. MP50-09 COMPARATIVE EFFECTIVENESS OF RADICAL CYSTECTOMY VERSUS BLADDER-SPARING TREATMENT FOR MUSCLE-INVASIVE UROTHELIAL CARCINOMA: A POPULATION-BASED REPORT.
24. MP70-09 PATTERNS OF USE OF BONE TARGETED THERAPY IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS: A POPULATION BASED STUDY
25. PD12-11 SURVIVAL BENEFIT OF RADICAL PROSTATECTOMY IN PATIENTS WITH CLINICALLY ADVANCED PROSTATE CANCER: ESTIMATIONS OF THE NUMBER NEEDED TO TREAT BASED ON COMPETING-RISKS ANALYSIS
26. MP61-06 NEOADJUVANT CHEMOTHERAPY IS NOT ASSOCIATED WITH WORSE SHORT-TERM OUTCOMES IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY: A POPULATION-BASED STUDY
27. 1836 CONDITIONAL SURVIVAL OF PATIENTS WITH RENAL CELL CARCINOMA TREATED WITH NEPHRECTOMY: A POPULATION BASED ANALYSIS
28. 1872 DISTRIBUTION OF METASTATIC SITES IN BLADDER CANCER: A POPULATION-BASED ANALYSIS
29. 1681 A NON-CANCER RELATED SURVIVAL BENEFIT IS ASSOCIATED WITH PARTIAL NEPHRECTOMY
30. 1591 AGE, COMORBIDITIES, AND RACE ARE PREDICTORS TO UNDERGO RADICAL CYSTECTOMY AT LOW VOLUME INSTITUTIONS
31. 1797 THE RISK OF IN-HOSPITAL MORTALITY AFTER CYTOREDUCTIVE NEPHRECTOMY: AN ASSESSMENT BASED ON PATIENT CHARACTERISTICS AND POSTOPERATIVE OUTCOMES DURING HOSPITALIZATION
32. 1686 INCREASING RATES OF ACTIVE SURVEILLANCE RELATIVE TO SURGICAL MANAGEMENT IN PATIENTS DIAGNOSED WITH T1AN0M0 RENAL CELL CARCINOMA
33. 1798 NO SURVIVAL BENEFIT IS ASSOCIATED WITH INCREASING EXTENT OF LYMPH NODE DISSECTION AT NEPHRECTOMY IN PATIENTS WITH POSITIVE LYMPH NODES: A CRITICAL RE-ANALYSIS
34. 1678 PARTIAL NEPHRECTOMY IS NOT ASSOCIATED WITH AN OTHER-CAUSE MORTALITY BENEFIT IN PATIENTS AGED ≥75 YEARS AND/OR MULTIPLE COMORBIDITIES WITH SMALL RENAL MASSES
35. 709 OLDER AND SICKER RENAL CELL CARCINOMA PATIENTS ARE OPERATED AT LOW VOLUME HOSPITALS
36. 1293 ACTIVE SURVEILLANCE MAY INCREASE THE RISK OF CANCER-SPECIFIC MORTALITY RELATIVE TO PARTIAL OR RADICAL NEPHRECTOMY: A COMPETING-RISKS ANALYSIS
37. 1119 A RE-ASSESSMENT OF 30-, 60- AND 90-DAY MORTALITY AFTER RADICAL PROSTATECTOMY
38. 643 PROPENSITY-SCORE MATCHED COMPARISON OF PERIOPERATIVE OUTCOMES BETWEEN OPEN AND LAPAROSCOPIC NEPHROURETERECTOMY: A NATIONAL SERIES
39. 570 AN ANALYSIS OF PATIENTS WITH T2 RENAL CELL CARCINOMA ACCORDING TO TUMOR SIZE: A POPULATION-BASED ANALYSIS
40. 1799 IN-HOSPITAL MORTALITY AFTER CYTOREDUCTIVE NEPHRECTOMY: A POPULATION-BASED ANALYSIS ACCORDING TO DISTRIBUTION OF METASTATIC SITES
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.